Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

PURPOSE: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma–reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT). PATIENTS AND METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, David J., Shah, Nina, Wu, Juan, Logan, Brent, Bisharat, Lina, Callander, Natalie, Cheloni, Giulia, Anderson, Kenneth, Chodon, Thinle, Dhakal, Binod, Devine, Steve, Somaiya Dutt, Poorvi, Efebera, Yvonne, Geller, Nancy, Ghiasuddin, Haider, Hematti, Peiman, Holmberg, Leona, Howard, Alan, Johnson, Bryon, Karagkouni, Dimitra, Lazarus, Hillard M., Malek, Ehsan, McCarthy, Philip, McKenna, David, Mendizabal, Adam, Nooka, Ajay, Munshi, Nikhil, O'Donnell, Lynn, Rapoport, Aaron P., Reese, Jane, Rosenblatt, Jacalyn, Soiffer, Robert, Stroopinsky, Dina, Uhl, Lynne, Vlachos, Ioannis S., Waller, Edmund K., Young, James W., Pasquini, Marcelo C., Avigan, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690096/
https://www.ncbi.nlm.nih.gov/pubmed/37463058
http://dx.doi.org/10.1158/1078-0432.CCR-23-0235

Ejemplares similares

Ejemplares similares